<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307189</url>
  </required_header>
  <id_info>
    <org_study_id>CER1199</org_study_id>
    <nct_id>NCT01307189</nct_id>
  </id_info>
  <brief_title>Effects of Tiotropium on Walking Capacity in Patients With COPD</brief_title>
  <official_title>Effects of Tiotropium on Walking Capacity in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test the following hypothesis:&#xD;
&#xD;
      A) The acute and long-term (3 weeks) bronchodilator-induced changes in exercise tolerance and&#xD;
      in the physiological response during the endurance shuttle walk will be greater with&#xD;
      tiotropium compared to placebo in COPD patients.&#xD;
&#xD;
      B) Three weeks of bronchodilation will be associated with increase activity of daily living&#xD;
      as evaluated using the London Chest Activity Daily Living scale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      The purpose of this study is to compare the acute bronchodilator-induced changes in exercise&#xD;
      tolerance during the endurance shuttle walk between tiotropium and placebo in COPD patients.&#xD;
      Also, it will evaluate the physiological response (VE, VO2, VCO2, and heart rate) during the&#xD;
      endurance shuttle walk in patients with COPD patients. Finally, it will compare the long-term&#xD;
      (3 weeks) bronchodilator-induced changes in exercise tolerance during the endurance shuttle&#xD;
      walk between tiotropium and placebo in COPD patients and evaluate the impact of long-term (3&#xD;
      weeks) bronchodilation on activity of daily living evaluated using the London Chest Activity&#xD;
      Daily Living scale.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This will be a double-blind, randomized and parallel-group study. Due to the long action&#xD;
      duration of tiotropium (up to 4 weeks), a cross-over design, as we used in our ipratropium&#xD;
      versus placebo study, is not appropriate in the present study. The study will require five&#xD;
      visits at the Centre de recherche de l'Hopital Laval. The first visit will include review of&#xD;
      the consent form, pulmonary function testing, and a maximal incremental shuttle walk. The&#xD;
      following two visits (Visit 2 and 3) will be used to familiarize the participants to the&#xD;
      shuttle endurance walking test. Salbutamol and ipratropium bromide will be stopped 6 hours&#xD;
      prior to these visits while the remaining medication allowed during the study period (see&#xD;
      below) will be continued as prescribed. The goal of the familiarization will be to reduce the&#xD;
      learning effect that typically occurs when an individual completes the same endurance test&#xD;
      several times 3. On visit 4, patients will be randomized to receive one of the two&#xD;
      treatments: placebo or tiotropium 18 ug (Spiriva) using the handihaler device. Pulmonary&#xD;
      function testing will then be performed and the London Chest Activity Daily Living scale will&#xD;
      be administered. Two hours following the inhalation of the first study dose, pulmonary&#xD;
      function testing will be repeated and the patients will perform an endurance shuttle walk.&#xD;
      They will be provided enough medication for the study duration and discharged. The same&#xD;
      procedure as Visit 4 will be completed three weeks later, on visit 5.&#xD;
&#xD;
      Data analysis:&#xD;
&#xD;
      The main outcome will be endurance time at day 21. This variable will be compared between the&#xD;
      two treatment arms using an unpaired t-test. The endurance time at day 0 will also be&#xD;
      compared between the two treatment arms using the same procedure. The time course of the&#xD;
      cardiorespiratory parameters and dyspnea over time will be compared between the two exercise&#xD;
      modalities. Comparisons will be done using a repeated measure design (ANOVA). Significance&#xD;
      level will be set at a p value of 0.05. The two familiarization endurance shuttle walk tests&#xD;
      performed at day -10 and day -5 will be used to evaluate the test-retest variability of this&#xD;
      procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time during an endurance shuttle walk</measure>
    <time_frame>acute response (2.5 hours) following the administration of the active and comparison drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the long-term bronchodilator-induced changes in exercise tolerance during the endurance shuttle walk</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of long-term bronchodilation on activity of daily living evaluated using the London Chest Activity Daily Living scale</measure>
    <time_frame>three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio-respiratory responses during an endurance shutlle walk</measure>
    <time_frame>acute response following the administration of the study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium diskus inhalation powder, 18ug, once daily</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo diskus inhalation powder, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 50 years, smoking history &gt; 10 packs/year, FEV1 &lt; 70% of predicted and FEV1/FVC&#xD;
             &lt; 70%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  respiratory exacerbation within the 2 months preceding the study, history of asthma,&#xD;
             significant O2 desaturation (SaO2 &lt; 85%) at rest or during exercise, presence of&#xD;
             another pathology that could influence exercise tolerance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Maltais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de recherche de l'IUCPQ</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr François Maltals</name_title>
    <organization>Laval University</organization>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>Exercise</keyword>
  <keyword>Endurance shuttle walking test</keyword>
  <keyword>Bronchodilation</keyword>
  <keyword>Tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

